Stocktoria
ANAPTYSBIO, INC ANAB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-01-26
ANAPTYSBIO, INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| R&D expense | — | — | — | $88.8M | $98.5M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $164,000 | $3,000 | -$4,000 | $24,000 | $0 |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| EPS (diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M |
| Cash & equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Shareholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M |
Source: SEC EDGAR filings · CIK 0001370053 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.